A new American study has found that women with high-risk of breast cancer are often reluctant to take the preventive drug tamoxifen.
A team at the University of Michigan Comprehensive Cancer Center developed a decision aid to inform women about the risks and benefits of tamoxifen use.
The U-M decision was tailored to each woman's health history and was aimed at women who had a high possibility of developing breast cancer in the next five years.
Lead author Angela Fagerlin, and an associate professor of internal medicine at the U-M Medical School, said: "Tailored information is critical because the risks and benefits vary across women. This is one of the most detailed tailored decision aids to address breast cancer prevention. The information about the risks and benefits of tamoxifen was tailored to each woman's health history. That means, when women read this decision aid, they learned about how the drug was likely to affect them given their age, race, breast cancer history and medical history."
She added: "For any given woman, there is not a right or wrong answer in regards to whether she should take tamoxifen to prevent a first diagnosis of breast cancer. The goal of decision aids is to explain the risks and benefits in a clear way so that the woman is able to weigh these factors and make an informed decision about what is best for her."